These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 9179542)

  • 1. Comparison of the effect of two low-density lipoprotein receptor class mutations on coronary heart disease among French-Canadian patients heterozygous for familial hypercholesterolaemia.
    Vohl MC; Gaudet D; Moorjani S; Tremblay G; Perron P; Gagné C; Lesiège D; Bergeron J; Lupien PJ; Després JP
    Eur J Clin Invest; 1997 May; 27(5):366-73. PubMed ID: 9179542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of receptor negative versus receptor defective mutations in the LDL-receptor gene to angiographically assessed coronary artery disease among young (25-49 years) versus middle-aged (50-64 years) men.
    Gaudet D; Vohl MC; Couture P; Moorjani S; Tremblay G; Perron P; Gagné C; Després JP
    Atherosclerosis; 1999 Mar; 143(1):153-61. PubMed ID: 10208490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterozygous familial hypercholesterolemia in children: low-density lipoprotein receptor mutational analysis and variation in the expression of plasma lipoprotein-lipid concentrations.
    Torres AL; Moorjani S; Vohl MC; Gagné C; Lamarche B; Brun LD; Lupien PJ; Després JP
    Atherosclerosis; 1996 Sep; 126(1):163-71. PubMed ID: 8879444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relative contribution of low-density lipoprotein receptor and lipoprotein lipase gene mutations to angiographically assessed coronary artery disease among French Canadians.
    Gaudet D; Vohl MC; Julien P; Tremblay G; Perron P; Gagné C; Bergeron J; Moorjani S; Després JP
    Am J Cardiol; 1998 Aug; 82(3):299-305. PubMed ID: 9708657
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterozygous familial hypercholesterolaemia: the influence of the mutation type of the low-density-lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment.
    Vuorio AF; Ojala JP; Sarna S; Turtola H; Tikkanen MJ; Kontula K
    J Intern Med; 1995 Jan; 237(1):43-8. PubMed ID: 7830029
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein(a) in homozygous familial hypercholesterolemia.
    Kraft HG; Lingenhel A; Raal FJ; Hohenegger M; Utermann G
    Arterioscler Thromb Vasc Biol; 2000 Feb; 20(2):522-8. PubMed ID: 10669652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Concentrations of the atherogenic Lp(a) are elevated in FH.
    Lingenhel A; Kraft HG; Kotze M; Peeters AV; Kronenberg F; Kruse R; Utermann G
    Eur J Hum Genet; 1998 Jan; 6(1):50-60. PubMed ID: 9781014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lp(a) levels and atherosclerotic vascular disease in a sample of patients with familial hypercholesterolemia sharing the same gene defect.
    Carmena R; Lussier-Cacan S; Roy M; Minnich A; Lingenhel A; Kronenberg F; Davignon J
    Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):129-36. PubMed ID: 8548413
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between apolipoprotein(a) phenotype, lipoprotein(a) concentration in plasma, and low density lipoprotein receptor function in a large kindred with familial hypercholesterolemia due to the pro664----leu mutation in the LDL receptor gene.
    Soutar AK; McCarthy SN; Seed M; Knight BL
    J Clin Invest; 1991 Aug; 88(2):483-92. PubMed ID: 1830890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of clinical diagnosis criteria of familial ligand defective apoB 100 and lipoprotein phenotype comparison between LDL receptor gene mutations affecting ligand-binding domain and the R3500Q mutation of the apoB gene in patients from a South European population.
    Ejarque I; Real JT; Martinez-Hervas S; Chaves FJ; Blesa S; Garcia-Garcia AB; Millan E; Ascaso JF; Carmena R
    Transl Res; 2008 Mar; 151(3):162-7. PubMed ID: 18279815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of genetic defects on atherosclerosis in patients suspected of familial hypercholesterolaemia.
    Descamps OS; Gilbeau JP; Leysen X; Van Leuven F; Heller FR
    Eur J Clin Invest; 2001 Nov; 31(11):958-65. PubMed ID: 11737238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma Lp(a) values in familial hypercholesterolemia and its relation to coronary heart disease.
    Real JT; Ascaso JF; Chaves FJ; Tenés S; Priego MA; Puig O; Armengod ME; Carmena R
    Nutr Metab Cardiovasc Dis; 1999 Feb; 9(1):41-4. PubMed ID: 10726108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation.
    Ferrières J; Lambert J; Lussier-Cacan S; Davignon J
    Circulation; 1995 Aug; 92(3):290-5. PubMed ID: 7634440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation.
    Alonso R; Andres E; Mata N; Fuentes-Jiménez F; Badimón L; López-Miranda J; Padró T; Muñiz O; Díaz-Díaz JL; Mauri M; Ordovás JM; Mata P;
    J Am Coll Cardiol; 2014 May; 63(19):1982-9. PubMed ID: 24632281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type III dyslipoproteinemia in patients heterozygous for familial hypercholesterolemia and apolipoprotein E2. Evidence for a gene-gene interaction.
    Hopkins PN; Wu LL; Schumacher MC; Emi M; Hegele RM; Hunt SC; Lalouel JM; Williams RR
    Arterioscler Thromb; 1991; 11(5):1137-46. PubMed ID: 1680391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations.
    Tada H; Kawashiri MA; Yoshida T; Teramoto R; Nohara A; Konno T; Inazu A; Mabuchi H; Yamagishi M; Hayashi K
    Circ J; 2016; 80(2):512-8. PubMed ID: 26632531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotype of the mutant LDL receptor allele is associated with LDL particle size heterogeneity in familial hypercholesterolemia.
    Hogue JC; Lamarche B; Gaudet D; Tremblay AJ; Després JP; Gagné C; Couture P
    Atherosclerosis; 2006 Jan; 184(1):163-70. PubMed ID: 15899484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical expression of familial hypercholesterolemia in clusters of mutations of the LDL receptor gene that cause a receptor-defective or receptor-negative phenotype.
    Bertolini S; Cantafora A; Averna M; Cortese C; Motti C; Martini S; Pes G; Postiglione A; Stefanutti C; Blotta I; Pisciotta L; Rolleri M; Langheim S; Ghisellini M; Rabbone I; Calandra S
    Arterioscler Thromb Vasc Biol; 2000 Sep; 20(9):E41-52. PubMed ID: 10978268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in the phenotype between children with familial defective apolipoprotein B-100 and familial hypercholesterolemia.
    Pimstone SN; Defesche JC; Clee SM; Bakker HD; Hayden MR; Kastelein JJ
    Arterioscler Thromb Vasc Biol; 1997 May; 17(5):826-33. PubMed ID: 9157944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic and environmental factors affecting the response to statin therapy in patients with molecularly defined familial hypercholesterolaemia.
    Miltiadous G; Xenophontos S; Bairaktari E; Ganotakis M; Cariolou M; Elisaf M
    Pharmacogenet Genomics; 2005 Apr; 15(4):219-25. PubMed ID: 15864114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.